Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Oct 19;10(10):CD004730.
doi: 10.1002/14651858.CD004730.pub5.

Drug treatments for managing cystic fibrosis-related diabetes

Gary M Onady  1 , Adrienne Stolfi  2
Affiliations
Meta-Analysis

Drug treatments for managing cystic fibrosis-related diabetes

Gary M Onady et al. Cochrane Database Syst Rev. .

Abstract

Background: The Cystic Fibrosis Foundation recommends both short-term and long-acting insulin therapy when cystic fibrosis-related diabetes (CFRD) has been diagnosed. Diagnosis is based on: an elevated fasting blood glucose level greater than 6.94 mmol/L (125 mg/dL); or oral glucose tolerance tests greater than 11.11 mmol/L (200 mg/dL) at two hours; or symptomatic diabetes for random glucose levels greater than 11.11 mmol/L (200 mg/dL); or glycated hemoglobin levels of at least 6.5%. This is an update of a previously published review.

Objectives: To establish the effectiveness of insulin and oral agents for managing diabetes in people with cystic fibrosis in relation to blood sugar levels, lung function and weight management.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. We also handsearched abstracts from pulmonary symposia and the North American Cystic Fibrosis Conferences. Date of most recent register search: 10 September 2020. We searched online trials registries; date of most recent searches: 21 March 2020.

Selection criteria: Randomized controlled trials comparing all methods of pharmacological diabetes therapy in people with diagnosed CFRD.

Data collection and analysis: Two authors independently extracted data and assessed the risk of bias in the included studies. Authors also used GRADE to assess the quality of the evidence.

Main results: The searches identified 29 trials (45 references). Four included trials provide results: one short-term single-center cross-over trial (seven adults) comparing insulin with oral repaglinide and no medication in adults with CFRD and normal fasting glucose; one long-term multicenter trial (61 adults with CFRD) comparing insulin with oral repaglinide and placebo; one long-term multicenter trial (67 adults) comparing insulin with oral repaglinide; and one 12-week single-center cross-over trial (20 adults) comparing the long-acting insulin glargine to short-term neutral protamine Hagedorn insulin. Two ongoing trials of newly approved incretin mimics have been noted for possible future inclusion. Downgrading of the quality of the evidence was mainly due to risks of bias across all domains, but particularly due to concerns surrounding allocation concealment and selective reporting. There were also some concerns due to imprecision from small sample sizes and low event rates. Finally, there may be some bias due to the amounts of insulin and repaglinide given not being comparable. Data from one trial comparing insulin to placebo (39 participants) did not show any difference between groups for the primary outcomes of blood glucose levels (very low-quality evidence), lung function (low-quality evidence) or nutritional status (low-quality evidence). Similarly, no differences between groups were seen for the secondary outcomes of number of hypoglycemic episodes (low-quality evidence), secondary infection complications or quality of life (QoL). These results were mirrored in the narrative reports for the second trial in this comparison (seven participants). Data from the one-year trial comparing repaglinide to placebo (38 participants), showed no differences between groups for the primary outcomes of blood glucose levels (very low-quality evidence), lung function (low-quality evidence) and nutritional status (low-quality evidence). Also, no differences were seen between groups for the secondary outcomes of number of hypoglycemic episodes (low-quality evidence), secondary infection complications or QoL. These findings were mirrored in the narrative reports for the second trial (n = 7) in this comparison. Three trials compared insulin to repaglinide (119 participants). Data from one trial (n = 67) showed no difference in blood glucose levels at either 12 months (high-quality evidence) or 24 months; narrative reports from one trial (45 participants) reported no difference between groups, but the second trial (7 participants) reported a beneficial effect of insulin over repaglinide. Two trials (112 participants) found no difference between insulin and repaglinide in lung function or nutritional status (moderate-quality evidence). Two trials (56 participants) reported no difference in the number of hypoglycemic episodes (low-quality evidence). One trial (45 participants) reported no difference between groups in secondary infections and cystic fibrosis QoL. The single trial comparing glargine to neutral protamine Hagedorn insulin did not report directly on the review's primary outcomes, but did report no differences between groups in post-prandial glucose values and weight; neither group reported infectious complications. There was no difference in episodes of hypoglycemia (very low-quality evidence) and while there was no difference reported in QoL, all participants opted to continue treatment with glargine after the trial was completed. Mortality was not reported by any trial in any comparison, but death was not given as a reason for withdrawal in any trial.

Authors' conclusions: This review has not found any conclusive evidence that any agent has a distinct advantage over another in controlling hyperglycemia or the clinical outcomes associated with CFRD. Given the treatment burden already experienced by people with cystic fibrosis, oral therapy may be a viable treatment option. While some cystic fibrosis centers use oral medications to help control diabetes, the Cystic Fibrosis Foundation (USA) clinical practice guidelines support the use of insulin therapy and this remains the most widely-used treatment method. Randomized controlled trials specifically related to controlling diabetes and its impact on the course of pulmonary disease process in cystic fibrosis continue to be a high priority. Specifically, investigators should evaluate adherence to different therapies and also whether there is benefit in using additional hypoglycemic agents as well as the newly approved incretin mimics. Agents that potentiate insulin action, especially agents with additional anti-inflammatory potential should also be further investigated as adjuvant therapy to insulin.

Trial registration: ClinicalTrials.gov NCT00662714.

PubMed Disclaimer

Conflict of interest statement

Gary Onady served on the Cystic Fibrosis Related Diabetes Guideline committee, with these Guidelines published in Diabetes Care in December 2010. He wrote the management component of that manuscript. This position has in no way influenced this subsequent and more recent review. In fact, this review puts into question the recommendations made in that earlier publication. He also serves on the Cystic Fibrosis Foundation's Center Committee, whose work is totally devoted to the clinical accreditation of CF Centers across the USA, and does not involve details as to the subject matter involved in this Cochrane Review. He has received travel and accomodation expenses from the Cystic Fibrosis Foundation.

Adrienne Stolfi declares no known potential conflict of interest.

Figures

1.1
1.1. Analysis
Comparison 1: Insulin versus placebo, Outcome 1: Change in FEV1 (% predicted)
1.2
1.2. Analysis
Comparison 1: Insulin versus placebo, Outcome 2: Change in FVC (% predicted)
1.3
1.3. Analysis
Comparison 1: Insulin versus placebo, Outcome 3: Change in BMI
1.4
1.4. Analysis
Comparison 1: Insulin versus placebo, Outcome 4: Hypoglycemia
2.1
2.1. Analysis
Comparison 2: Repaglinide versus placebo, Outcome 1: Change in FEV1 (% predicted)
2.2
2.2. Analysis
Comparison 2: Repaglinide versus placebo, Outcome 2: Change in FVC (% predicted)
2.3
2.3. Analysis
Comparison 2: Repaglinide versus placebo, Outcome 3: Change in BMI
2.4
2.4. Analysis
Comparison 2: Repaglinide versus placebo, Outcome 4: Hypoglycemia
3.1
3.1. Analysis
Comparison 3: Insulin versus repaglinide, Outcome 1: Change in HbA1c concentration ( % )
3.2
3.2. Analysis
Comparison 3: Insulin versus repaglinide, Outcome 2: Change in FEV1 (% predicted)
3.3
3.3. Analysis
Comparison 3: Insulin versus repaglinide, Outcome 3: Change in FVC (% predicted)
3.4
3.4. Analysis
Comparison 3: Insulin versus repaglinide, Outcome 4: Change in BMI
3.5
3.5. Analysis
Comparison 3: Insulin versus repaglinide, Outcome 5: Change in BMI z score
3.6
3.6. Analysis
Comparison 3: Insulin versus repaglinide, Outcome 6: Hypoglycemia
4.1
4.1. Analysis
Comparison 4: NPH insulin versus glargine, Outcome 1: Glucose levels (mg/dl)
4.2
4.2. Analysis
Comparison 4: NPH insulin versus glargine, Outcome 2: Change in weight (kg)
4.3
4.3. Analysis
Comparison 4: NPH insulin versus glargine, Outcome 3: Fat mass by DEXA (kg)
4.4
4.4. Analysis
Comparison 4: NPH insulin versus glargine, Outcome 4: Lean mass by DEXA (kg)
4.5
4.5. Analysis
Comparison 4: NPH insulin versus glargine, Outcome 5: Hypoglycemic events per participant
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Ballmann 2018b {published data only}
    1. Ballmann M, Hubert D, Assael BM, Kronfeld K, Honer M, Holl RW, et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics 2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: ] - PMC - PubMed
    1. Ballmann M, Hubert D, Assael BM, Mosnier-Pudar H, Barao Ocampo M, Scheunig N, et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology 2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b]
    1. Ballmann M, Hubert D, Assael BM, Mosnier-Pudar H, Smaczny C, Kessler L, et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis 2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a]
    1. Ballmann M, Hubert D, Assael BM, Staab D, Hebestreit A, Naehrlich L, et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology 2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X] - DOI - PubMed
    1. Schmid K, Fink K, Holl RW, Hebestreit H, Ballmann M. Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society 2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: ] [SI: ClinicalTrials.gov/NCT00662714] - PubMed
Grover 2008 {published and unpublished data}
    1. Grover P, Thomas W, Moran A. Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis 2008;7(2):134-6. [CFGD REGISTER: CO39] - PMC - PubMed
Moran 2001 {published data only}
    1. Milla CE, Phillips J, Moran A. Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology 2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] - PubMed
    1. Moran A, Phillips J, Milla C. Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care 2001;24(10):1706-10. [CFGD REGISTER: CO34b] - PubMed
Moran 2009 {published and unpublished data}
    1. Moran A, Pekow P, Grover P, Zorn M, Slovis B, Pilewski J, et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care 2009;32(10):1783-8. [CFGD REGISTER: CO43] - PMC - PubMed

References to studies excluded from this review

Beaudoin 2015 {published data only}
    1. Beaudoin N, Bouvet GF, Coriati A, Rabasa-Lhoret R, Berthiaume Y. Combined exercise training improves glycemic control in adult with cystic fibrosis. Medicine and Science in Sports and Exercise 2017;49(2):231-7. [CFGD REGISTER: CO62b] - PubMed
    1. Beaudoin N, Bouvet GF, Coriati A, Rabasa-Lhoret R, Berthiaume Y. Combined exercise training improves glycemic control in adult with cystic fibrosis. Medicine and Science in Sports and Exercise 2017;49(2):231-7. Supplemental digital content. [CFGD REGISTER: CO62c] - PubMed
    1. Beaudoin N, Bouvet GF, Rabasa-Lhoret R, Berthiaume Y. Effects of a partially supervised combined exercise program on glycemic control in cystic fibrosis: pilot study. Pediatric Pulmonology 2015;50 Suppl 41:367. [ABSTRACT NO.: 466] [CFGD REGISTER: CO62a]
Borowitz 2005 {published data only}
    1. Borowitz D, Goss C, Limauro S, Murray F, Casey S, Cohen M. A dose-ranging study of efficacy of TheraCLEC-Total for treatment of pancreatic insufficiency. Pediatric Pulmonology 2005;40 (Suppl 28):348. [CFGD REGISTER: GN203a]
    1. Borowitz D, Goss CH, Limauro S, Murray F, Casey S, Cohen M, et al. A phase 2 study of TheraCLEC-Total enzymes in CF patients with pancreatic insufficiency (PI). Pediatric Pulmonology 2005;40 (Suppl 28):142. [CFGD REGISTER: GN203b]
    1. Borowitz D, Konstan MW, Goss C, Limauro SE, Murray FT, Casey S, et al. Treatment with ALTU-135 results in a positive inverse relationship between coefficient of fat absorption with stool weight in subjects with cystic fibrosis-related pancreatic insufficiency. Journal of Cystic Fibrosis 2006;5 Suppl:S56. [CFGD REGISTER: GN203c]
    1. Borowitz D, Konstan MW, Goss C, Limauro SE, Murray FT. Enhanced coefficient of fat absorption using a novel pancreatic enzyme preparation, ALTU-135, with concomitant use of a proton pump inhibitor. Journal of Cystic Fibrosis 2006;5 Suppl:S56. [CFGD REGISTER: CO203d]
    1. Murray FT, Borowitz D, Konstan MW, Limauro SE, Goss C. Changes in coefficients of fat and nitrogen absorption in subjects with cystic fibrosis, pancreatic insufficiency, and cystic fibrosis-related diabetes mellitus receiving a novel pancreatic enzyme product, ALTU-135. Pediatric Pulmonology 2006;41 Suppl 29:386. [CFGD REGISTER: GN203e]
Chernoff 2002 {published data only}
    1. Chernoff RG, Ireys HT, DeVet KA, Kim YJ. A randomized, controlled trial of a community-based support program for families of children with chronic illness: pediatric outcomes. Archives of Pediatrics and Adolescent Medicine 2002;156(6):533-9. [CFGD REGISTER: MH13b] - PubMed
    1. Ireys HT, Chernoff R, DeVet KA, Kim Y. Maternal outcomes of a randomized controlled trial of a community-based support program for families of children with chronic illnesses. Archives of Pediatrics and Adolescent Medicine 2001;155(7):771-7. [CFGD REGISTER: MH13a] - PubMed
Driscoll 2009 {published data only}
    1. Driscoll KA, Johnson SB, Barker D, Quittner AL, Deeb LC, Geller DE, et al. Risk factors associated with depressive symptoms in caregivers of children with type 1 diabetes or cystic fibrosis. Journal of Pediatric Psychology 2010;35(8):814-22. [CFGD REGISTER: CO49b] 5500100000011199 - PMC - PubMed
    1. Driscoll KA, Johnson SB, Tang Y, Yang F, Deeb LC, Silverstein JH. Does blood glucose monitoring increase prior to clinic visits in children with type 1 diabetes? Diabetes Care 2011;34(10):2170-3. [CFGD REGISTER: CO49c] 5500100000011200 - PMC - PubMed
    1. Driscoll KA, Killian M, Johnson SB, Silverstein JH, Deeb LC. Predictors of study completion and withdrawal in a randomized clinical trial of a pediatric diabetes adherence intervention. Contemporary Clinical Trials 2009;30(3):212-20. [CFGD REGISTER: CO49a] 5500100000011198 - PMC - PubMed
Eiel 2018 {published data only}
    1. Eiel JN, Nyirjesy S, Peleckis AJ, De Leon D, Hadjiliadis D, Kubrak C, et al. Effects of GLP-1 and GIP on insulin secretion in glucose intolerant, pancreatic insufficient cystic fibrosis. Diabetes 2018;67(Supplement 1):A484. [CFGD REGISTER: CO68] - PMC - PubMed
    1. Kelly A, Nyirjesy S, Peleckis A, Eiel J, De Leon D, Hadjiliadis D, et al. Effect of GLP-1 and GIP on insulin secretion in glucose intolerant, pancreatic insufficient cystic fibrosis. Pediatric Pulmonology 2019;54 Suppl 2:222. [CENTRAL: CN-01988358] [CFGD REGISTER: CO68b] [EMBASE: 629388555]
    1. Nyirjesy SC, Sheikh S, Hadjiliadis D, De Leon DD, Peleckis AJ, Eiel JN, et al. β-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose ≥155 mg/dL. Pediatric Diabetes 2018;19(7):1173-82. [DOI: 10.1111/pedi.12700] - DOI - PMC - PubMed
Franzese 2005 {published data only}
    1. Franzese A, Spagnuolo MI, Sepe A, Valerio G, Mozzillo E, Raia V. Can glargine reduce the number of lung infections in patients with cystic fibrosis-related diabetes? Diabetes Care 2005;28(9):2333. - PubMed
Geyer 2019 {published data only}
    1. Geyer MC, Sullivan T, Tai A, Morton JM, Edwards S, Martin AJ, et al. Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: a randomized crossover trial. Diabetes, Obesity & Metabolism 2019;21:700-704. [CFGD REGISTER: CO69] - PubMed
Hardin 2009 {published data only}
    1. Hardin DS, Rice J, Rice M, Rosenblatt R. Use of the insulin pump in treat cystic fibrosis related diabetes. Journal of Cystic Fibrosis 2009;8(3):174-8. - PubMed
König 2005 {published data only}
    1. König P, Goldstein D, Poehlmann M, Rife D, Ge B, Hewett J. Effect of nebulized albuterol on blood glucose in patients with diabetes mellitus with and without cystic fibrosis. Pediatric Pulmonology 2005;40(2):105-8. [CFGD REGISTER: CO23] - PubMed
Mahroukh 2005 {published data only}
    1. Mahroukh R, Chapman K, Stewart C, Kelly E, Hanna A, Wilson DC, et al. Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis. American Journal of Clinical Nutrition 2005;81(2):421-6. - PubMed
Marshall 2005 {published data only}
    1. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ, et al. Epidemiology of cystic fibrosis-related diabetes. Journal of Pediatrics 2005;146(5):681-7. - PubMed
Milla 2005 {published data only}
    1. Milla CE, Billings J, Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care 2005;28(9):2141-4. - PubMed
Minicucci 2012 {published data only}
    1. Minicucci L, Casciaro R, De Alessandri A, Haupt M, Caso M, Lucidi V, et al. Efficacy of slow release insulin in patients with cystic fibrosis and glucide intolerance. Journal of Cystic Fibrosis 2009;8 (Suppl 2):S82. [ABSTRACT NO.: 331] [CFGD REGISTER: CO42b]
    1. Minicucci L, Haupt M, Casciaro R, De Alessandri A, Bagnasco F, Lucidi V, et al. Slow-release insulin in cystic fibrosis patients with glucose intolerance: a randomized clinical trial. Pediatric Diabetes 2012;13(2):197-202. [CFGD REGISTER: CO42c] - PubMed
    1. Minicucci L. New diagnostic and therapeutic approaches in cystic fibrosis related diabetes (CFRD). Journal of Cystic Fibrosis 2008;7(Suppl 3):S6. [ABSTRACT NO.: R25] [CFGD REGISTER: CO42a]
NCT01149005 {published data only}
    1. NCT01149005. Cystic Fibrosis (CF) Exacerbation and Insulin Treatment. clinicaltrials.gov/show/nct01149005 (first posted 23 June 2010).
NCT02496780 {published data only (unpublished sought but not used)}
    1. NCT02496780. The impact of insulin therapy on protein turnover in pre-diabetic cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT02496780 (first posted 14 July 2015).
Onady 2006 {published data only}
    1. Onady GM, Langdon LJ. Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study. BMC Endocrine Disorders 2006;6:4. [PMID: ] - PMC - PubMed
Peraldo 1998 {published data only}
    1. Peraldo M, Fasulo A, Chiappini E, Milio C, Marianelli L. Evaluation of glucose tolerance and insulin secretion in cystic fibrosis patients. Hormone Research 1998;49(2):65-71. - PubMed
Reali 2006 {published data only}
    1. Reali MF, Festini F, Neri AS, Taccetti G, Repetto T, Chiarelli F, et al. Use of continuous subcutaneous insulin infusion in cystic fibrosis patients with cystic fibrosis-related diabetes awaiting transplantation. Journal of Cystic Fibrosis 2006;5(1):67-8. - PubMed
Sc 2010 {published data only}
    1. Sc NN, Shoseyov D, Kerem E, Zangen DH. Patients with cystic fibrosis and normoglycemia exhibit diabetic glucose tolerance during pulmonary exacerbation. Journal of Cystic Fibrosis 2010;9(3):199-204. [DOI: 10.1016/j.jcf.2010.02.001] - DOI - PubMed
Sulli 2007 {published data only}
    1. Sulli N, Bertasi S, Zullo S, Shashaj B. Use of continuous subcutaneous insulin infusion in patients with cystic fibrosis related diabetes: Three case reports. Journal of Cystic Fibrosis 2007;6(3):237-40. - PubMed
Teeter 2004 {published data only}
    1. Teeter JG, the Exubera ® Phase 3 Study Group, Pfizer Global Research and Development GCU . One-year pulmonary safety and efficacy of inhaled insulin as adjunctive therapy in type 2 diabetes patients poorly controlled on oral agent monotherapy. European Respiratory Journal 2004;24(Suppl 48):P3773. [CFGD REGISTER: CO36]
Ward 1999 {published data only}
    1. Ward SA, Tomezsko JL, Holsclaw DS, Paolone AM. Energy expenditure and substrate utilization in adults with cystic fibrosis and diabetes mellitus. American Journal of Clinical Nutrition 1999;69(5):913-9. - PubMed

References to studies awaiting assessment

de Lind 2014 {published data only}
    1. Lind van Wijngaarden-van den Berg JMW, Meer R, Heijerman HGM. A placebo-controlled trial of insulin therapy with or without adjuvant metformin in patients with cystic fibrosis-related diabetes (CFRD). Journal of Cystic Fibrosis 2014;13 Suppl 2:S12. [ABSTRACT NO.: WS6.4] [CENTRAL: 996580] [CFGD REGISTER: CO56 ]

References to ongoing studies

NCT01851694 {published data only (unpublished sought but not used)}
    1. NCT01851694. Beta-cell Response to Incretin Hormones in Cystic Fibrosis. clinicaltrials.gov/show/nct01851694 (first posted 10 May 2013).
NCT02202876 {published data only (unpublished sought but not used)}
    1. NCT02202876. Redox Imbalance and the Development of Cystic Fibrosis Diabetes. clinicaltrials.gov/show/nct02202876 (first posted 29 July 2014).

Additional references

ADA 2004
    1. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;27:S15-35. - PubMed
Ballmann 2018a
    1. Ballmann, MW, Wosnick J, Fischer D. Treatment of CFRD diagnosed by annual OGT screening: real life data from a longitudinal registry study from Germany. Pediatric Pulmonology 2018;53 Supplement 2:398. [ABSTRACT NO.: 651]
Culler 1994
    1. Culler FL, McKean LP, Buchanan CN, Caplan DB, Meacham LR. Glipizide treatment of patients with cystic fibrosis and impaired glucose tolerance. Journal of Pediatric Gastroenterology and Nutrition 1994;18(3):375-8. - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, A Vail. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. - PubMed
Filipova 2017
    1. Filipova E, Uzunova K, Kalinov K, Vekov T. Pioglitazone and the risk of bladder cancer: a meta-analysis. Diabetes Therapy 2017;8(4):705-26. [DOI: 10.1007/s13300-017-0273-4] - DOI - PMC - PubMed
Finkelstein 1988
    1. Finkelstein SM, Wielinski CL, Elliott GR, Warwick WJ, Barbosa J, Wu SC, et al. Diabetes mellitus associated with cystic fibrosis. Journal of Pediatrics 1988;112(3):373-7. - PubMed
Hardin 1997
    1. Hardin DS, Sy JP. Effects of growth hormone treatment in children with cystic fibrosis: the National Cooperative Growth Study experience. Journal of Pediatrics 1997;131(1 Pt 2):S65-9. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. - PMC - PubMed
Higgins 2011
    1. Higgins JP, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Landers 1997
    1. Landers A, Mathalone B, Byi KM, Hodson ME. Diabetic retinopathy in patients with cystic fibrosis related diabetes (CFRD). Pediatric Pulmonology 1997;24 (Suppl 14):306.
Lanng 1994
    1. Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatrica 1994;83(8):849-53. - PubMed
Moheet 2017
    1. Moheet A, Moran A. CF-related diabetes: Containing the metabolic miscreant of cystic fibrosis. Pediatric Pulmonology 2017;52(S48):S37-S43. [DOI: 10.1002/ppul.23762] - DOI - PubMed
Moran 1991
    1. Moran A, Diem J, Klein DF, Levitt MD, Robertson RP. Pancreatic endocrine function in cystic fibrosis. Journal of Pediatrics 1991;118(5):715-23. - PubMed
Moran 2010
    1. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010;33(12):2697-708. - PMC - PubMed
Pu 2016
    1. Pu MZ, Christensen-Adad FC, Gonçalves AC, Minicucci WJ, Ribeiro JD, Ribeiro AF. Insulin therapy in patients with cystic fibrosis in the pre-diabetes stage: a systematic review. Revista Paulistade Pediatria 2016;34(3):367-73. [DOI: 10.1016/j.rpped.2015.12.010] - DOI - PMC - PubMed
Quittner 2009
    1. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8. - PMC - PubMed
Rosenecker 2001
    1. Rosenecker J, Eichler I, Barmeier H, Hardt H. Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents. Pediatric Pulmonlogy 2001;32(5):351-5. - PubMed
Schmid 2014
    1. Schmid K, Fink K, Holl RW, Hebestreit H, Ballmann M. Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis 2014;13(1):80-5. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, (editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Schwarzenberg 2007
    1. Schwarzenberg SJ, Thomas W, Olsen TW, Grover T, Walk D, Milla C, et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 2007;30(5):1056-61. - PubMed
Warren 2019
    1. Warren RE. Cystic fibrosis and insulin therapy: a reality check. Diabetic Medicine 2019;00:1-5. [DOI: 10.1111/dme.13959] - DOI - PubMed

References to other published versions of this review

Onady 2005
    1. Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No: CD004730. [DOI: 10.1002/14651858.CD004730.pub2] - DOI - PubMed
Onady 2013
    1. Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No: CD004730. [DOI: 10.1002/14651858.CD004730.pub3] - DOI - PubMed
Onady 2016
    1. Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database of Systematic Reviews 2016, Issue 4. Art. No: CD004730. [DOI: 10.1002/14651858.CD004730.pub4] - DOI - PubMed

Publication types

MeSH terms

Associated data